AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA BioTech GOSS Gossamer Sets September NDA Filing For Seralutinib In Pulmonary Arterial Hypertension; Stock Up July 27, 2026 — 11:51 am EDT Written by RTTNews.com for RTTNews -> (RTTNews) - Gossamer Bio, Inc. (GOSS) announced that following a productive Pre-NDA Type B meeting with the U.S. FDA and receipt of the official meeting minutes, the company is moving forward with a planned NDA submission for Seralutinib in pulmonary arterial hypertension in September 2026. If accepted for filing, Seralutinib could be eligible for an FDA approval decision in the third quarter of 2027. Pulmonary arterial hypertension (PAH) is a rare, progressive disease that causes high blood pressure in the lungs, leading to shortness of breath, fatigue, and heart failure. Current therapies often slow progression but do not fully address the unmet need for patients living with this condition. Seralutinib is an investigational, inhaled, small-molecule therapy designed to target key pathways involved in PAH and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company believes it has the potential to be a first-in-class treatment option. Alongside the regulatory update, Gossamer announced it has reacquired worldwide development and commercial rights to Seralutinib from Chiesi, giving the company full global control over the program. Management emphasized that this move secures the majority of long-term economics for shareholders and positions Gossamer to maximize the strategic and financial value of Seralutinib. The company also reported preliminary cash, cash equivalents, and marketable securities of approximately $57 million as of June 30, 2026. Through the exchange, Gossamer exchanged approximately $181.1 million, or 90.5%, of the $200 million aggregate principal amount of 2027 Notes outstanding for approximately $65.2 million of new 7.50% Convertible Senior Secured First Lien Notes due 2030, together with the applicable equity securities and warrants. Shareholders approved proposals related to a convertible note exchange and a reverse stock split, strengthening the capital structure ahead of the NDA filing. The company expects to effect the reverse stock split in or promptly following the third quarter of 2026. "This is a defining moment for Gossamer," said Faheem Hasnain, Chairman, Co-Founder and CEO of Gossamer, noting that years of disciplined execution have brought the company closer than ever to delivering a new medicine for PAH patients who need better options. GOSS has traded between $0.11 and $3.87 over the past year. The stock is currently trading at $0.19, up 41.16%. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Tags BioTech RTTNews Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges. More articles by this source -> Stocks mentioned GOSS More Related Articles This data feed is not available at this time. Data is currently not available • Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.